Well, this is all we really need to take notice of....
“The discontinuation of the GSK trial has no impact on Immutep’s three other product candidates all of which have different mechanisms of action, including its lead product candidate eftilagimod alpha. In addition, there is no impact to Immutep’s funding capacity for the development of its in-house programs. The Company remains in a robust operational and financial position with a cash runway beyond the end of calendar year 2022” end
Ann: Ulcerative Colitis Phase II Study of GSK2831781 Discontinued, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.8¢ |
Change
0.008(3.00%) |
Mkt cap ! $376.0M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.0¢ | 24.5¢ | $566.5K | 2.247M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 219168 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 683185 | 20 |
View Market Depth
| Last trade - 12.49pm 17/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |